Alopecia pipeline review H2 2018 just published
If you are want to study the Alopecia industry or intend to be, then this guide will provide you comprehensive outlook. It’s vital for you to keep your knowledge up to date by keeping research and development (R&D) of major players.
If you have a different set of players/manufacturers according to geography or needs regional or country segmented reports we can provide requirement according to your needs.
Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body.
Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.
Key Players included in the research study are Aclaris Therapeutics Inc, Allergan Plc, Almirall SA, AndroScience Corp, Berg LLC, BiologicsMD Inc, BirchBioMed Inc, Brickell Biotech Inc, Bristol-Myers Squibb Co, Cassiopea SpA, Concert Pharmaceuticals Inc, Daewoong Pharmaceutical Co Ltd, Dong-A Socio Holdings Co Ltd, Eli Lilly and Co, Energenesis Biomedical Co Ltd, Follica Inc, Histogen Inc, Japan Tobacco Inc, JW Pharmaceutical Corp, Kuhnil Pharmaceutical Co Ltd, Lee’s Pharmaceutical Holdings Ltd, Medivir AB, NovaLead Pharma Pvt Ltd, OliX Pharmaceuticals Inc, Pfizer Inc, Portola Pharmaceuticals Inc, Quark Pharmaceuticals Inc, RXi Pharmaceuticals Corp, Samumed LLC, Taisho Pharmaceutical Holdings Co Ltd & Tigo GmbH.
The guide features dormant and discontinued projects and covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 1, 9 and 1 respectively.
Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Alopecia pipeline guide helps in identifying and tracking emerging and major players moves in the market and their portfolios, enhances decision-making capabilities and helps to create effective marketing strategies to gain a competitive advantage in healthcare and pharmaceuticals industry. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The data and information sourced from the databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the latest key developments are captured on a real-time basis.
Extracts of Chapters from Alopecia – Pipeline Review, H2 2018
Chapter 1, to describe the definition, overview and Therapeutics Development of Alopecia.
Chapter2, to analyze the pipeline overview of companies, Universities/Institutes and the product development under by companies, Universities/Institutes.
Chapter3, Therapeutics Assessment of Alopecia by Target, Mechanism of Action, Route of Administration and by Molecule Type.
Chapter4, to display company profile involved in Therapeutics Development.
Chapter5, Drug profile product description, Mechanism of action and R&D Progress of Alopecia.
Chapter 6,7, to describe Alopecia Appendix, Methodology, Coverage, Secondary Research, Primary Research, Expert Panel Validation and Contact Us.
Objective of this study
– To provides a snapshot of the global therapeutic landscape of Alopecia.
– To reviews pipeline therapeutics for Alopecia by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprises, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Alopecia therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Alopecia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews the latest news related to pipeline therapeutics for Alopecia
This research report helps to
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Alopecia.
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Alopecia pipeline review